Becton, Dickinson and Company (NYSE:BDX) Shares Sold by Bank of New York Mellon Corp

Bank of New York Mellon Corp reduced its stake in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 42.6% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,869,455 shares of the medical instruments supplier's stock after selling 1,388,519 shares during the period. Bank of New York Mellon Corp owned approximately 0.65% of Becton, Dickinson and Company worth $428,217,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Smallwood Wealth Investment Management LLC acquired a new position in Becton, Dickinson and Company during the first quarter valued at $27,000. Alpine Bank Wealth Management acquired a new position in Becton, Dickinson and Company during the first quarter valued at $29,000. REAP Financial Group LLC lifted its position in Becton, Dickinson and Company by 75.3% during the fourth quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock valued at $29,000 after purchasing an additional 55 shares during the period. Picton Mahoney Asset Management lifted its position in Becton, Dickinson and Company by 61.4% during the fourth quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier's stock valued at $32,000 after purchasing an additional 54 shares during the period. Finally, Nexus Investment Management ULC acquired a new position in Becton, Dickinson and Company during the first quarter valued at $34,000. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP David Shan sold 1,166 shares of the stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $171.19, for a total transaction of $199,607.54. Following the sale, the executive vice president directly owned 4,575 shares in the company, valued at $783,194.25. This represents a 20.31% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.36% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. The Goldman Sachs Group downgraded shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $192.00 price objective for the company. in a research report on Friday, May 2nd. Stifel Nicolaus decreased their price objective on shares of Becton, Dickinson and Company from $280.00 to $224.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. Barclays decreased their price objective on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating for the company in a research report on Tuesday, June 3rd. Wall Street Zen downgraded shares of Becton, Dickinson and Company from a "buy" rating to a "hold" rating in a research report on Friday, May 2nd. Finally, Wells Fargo & Company downgraded shares of Becton, Dickinson and Company from an "overweight" rating to an "equal weight" rating in a research report on Thursday, May 1st. Eight research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $219.22.

Becton, Dickinson and Company Trading Up 1.1%

Shares of BDX stock traded up $1.86 during trading hours on Thursday, hitting $177.36. The company had a trading volume of 3,014,057 shares, compared to its average volume of 2,076,061. The company's fifty day moving average is $172.03 and its 200 day moving average is $206.75. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.13 and a quick ratio of 0.64. Becton, Dickinson and Company has a fifty-two week low of $163.33 and a fifty-two week high of $251.99. The stock has a market capitalization of $50.83 billion, a PE ratio of 33.85, a price-to-earnings-growth ratio of 1.32 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $3.35 EPS for the quarter, topping the consensus estimate of $3.28 by $0.07. Becton, Dickinson and Company had a net margin of 7.28% and a return on equity of 15.99%. The firm had revenue of $5.27 billion for the quarter, compared to analyst estimates of $5.35 billion. During the same period in the prior year, the business posted $3.17 EPS. The business's revenue for the quarter was up 4.5% compared to the same quarter last year. Research analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, June 30th. Shareholders of record on Monday, June 9th were issued a dividend of $1.04 per share. The ex-dividend date was Monday, June 9th. This represents a $4.16 dividend on an annualized basis and a yield of 2.35%. Becton, Dickinson and Company's dividend payout ratio (DPR) is presently 79.39%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.